EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Revolution Medicines's enterprise value is $4,551.67 Mil.
Revolution Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $4.57 Mil. Therefore, Revolution Medicines's EV-to-Revenue for today is 996.86.
The historical rank and industry rank for Revolution Medicines's EV-to-Revenue or its related term are showing as below:
RVMD'
s EV-to-Revenue Range Over the Past 10 Years
Min: 6.95 Med: 45.45 Max: 1096.49
Current: 996.86
During the past 7 years, the highest EV-to-Revenue of Revolution Medicines was 1096.49. The lowest was 6.95. And the median was 45.45.
RVMD's EV-to-Revenue is ranked worse than 94.61% of 1038
companies
in the Biotechnology industry
Industry Median: 7.97
vs RVMD: 996.86
Revolution Medicines EV-to-Revenue Historical Data
The historical data trend for Revolution Medicines's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Revolution Medicines's EV-to-Revenue
For the Biotechnology subindustry, Revolution Medicines's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revolution Medicines's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revolution Medicines's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Revolution Medicines's EV-to-Revenue falls into.
Revolution Medicines's current Enterprise Value is $4,551.67 Mil.
Revolution Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines's share price for today is $39.39.
Revolution Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Revolution Medicines's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Revolution Medicines (Revolution Medicines) Business Description
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVMD has been successfully added to your 